Antitumor properties of natural compounds and related molecules

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 3, 2013, Pages 203-215

  Robles Fernández, Inmaculada ^a   Rodríguez Serrano, Fernando ^a   Álvarez, Pablo J ^a   Ortiz, Raúl ^b   Rama, Ana R ^b   Prados, José ^a   Melguizo, Consolación ^a   Álvarez Manzaneda, Enrique ^a   Aránega, Antonia ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

Cancer therapy; Marine organisms; Microorganisms; Natural compounds; Patent; Vegetable

Indexed keywords

8 HYDROXY 2 METHYL 4 (3H) QUINAZOLINONE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; BAFILOMYCIN A1; BEVACIZUMAB; CARBOPLATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; ELISIDEPSIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; FLUOROURACIL; GEMCITABINE; INGENOL MEBUTATE; KAHALALIDE F; NATALIZUMAB; NATURAL PRODUCT; NAVELBINE; NICOTINAMIDE; PACLITAXEL; PALMEROLIDE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; ROMIDEPSIN; SAGOPILONE; SALINOSPORAMIDE A; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BARK; BIOLOGICAL ACTIVITY; CYTOTOXICITY; DNA FRAGMENTATION; DNA SEQUENCE; EXCISION REPAIR; HISTONE ACETYLATION; HUMAN; IC 50; MEDICINAL PLANT; NANOMEDICINE; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROSACEAE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AQUATIC ORGANISMS; BACTERIA; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL;

EID: 84888026704     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574891X113089990034     Document Type: Article

References (154)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide. Available at: http://globocan. iarc. fr. (Accessed on: November 6, 2012).
2. Sneader W. Drug Discovery: A History. John Wiley & Sons Inc: New York 2005.
3. De La Calle F. Fármacos de origen marino. Treballs de la SCB 2007; 58: 141-55.
4. Jarvis LM. Liquid gold mine. Chem Eng News 2007; 85(41): 22-8.
5. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4(3): 206-20.
6. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009; 8(1): 69-85.
7. Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res 2009; 59(6): 365-78.
8. Huang W-Y, Cai Y-Z, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: Potential use for cancer prevention. Nutr Cancer 2010; 62: 1-20.
9. Liu K-C, Huang A-C, Wu P-P, Lin H-Y, Chueh F-S, Yang J-S, et al. Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and-9 signaling pathways. Oncol Rep 2011; 26: 177-84.
10. Forester SC, Choy YY, Waterhouse AL, Oteiza PI. The anthocyanin metabolites gallic acid, 3-O-methylgallic acid, and 2, 4, 6-trihydroxybenzaldehyde decrease human colon cancer cell viability by regulating pro-oncogenic signals. Mol Carcinog 2012. doi: 10. 1002/mc. 21974.
11. Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 2010; 78: 181-8.
12. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005; 100: 72-9.
13. Bhanot A, Sharma R, Noolvi MN. Natural sources as potential anticancer agents: A review. Int J Phytomed 2011; 3: 9-26.
14. Gomez-Monterrey I, Campiglia P, Bertamino A, Aquino C, Sala M, Grieco P, et al. A novel quinone-based derivative (DTNQ-Pro) induces apoptotic death via modulation of heat shock protein expression in Caco-2 cells. Br J Pharmacol 2010; 160: 931-40.
15. Bringmann, G., Rüdenauer, S., Brun, R., Irmer, A., Bargou, R., Chatterjee, M., Voskobojnik, A. Antiinfective and antitumoral compounds isolated from tropical lianas. US20110059911 (2011).
16. Bringmann G, Feineis D. Stress-related polyketide metabolism of Dioncophyllaceae and Ancistrocladaceae. J Exp Bot 2001; 52(363): 2015-22.
17. Bringmann G, Rudenauer S, Irmer A, Bruhn T, Brun R, Heimberger T, et al. Antitumoral and antileishmanial dioncoquinones and ancistroquinones from cell cultures of Triphyophyllum peltatum (Dioncophyllaceae) and Ancistrocladus abbreviatus (Ancistrocladaceae). Phytochemistry 2008; 69(13): 2501-9.
18. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004; 64(9): 3243-55.
19. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332 (2): 281-92.
20. Serova M, Ghoul A, Benhadji KA, Faivre S, Le Tourneau C, Cvitkovic E, et al. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther 2008; 7(4): 915-22.
21. Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, et al. The protein kinase C agonist PEP005 (Ingenol 3-Angelate) in the treatment of human cancer: A balance between efficacy and toxicity. Toxins (Basel) 2010; 2(1): 174-94.
22. Hampson P, Kavanagh D, Smith E, Wang K, Lord JM, Ed Rainger G. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother 2008; 57(8): 1241-51.
23. Ogbourne, S. M., Suhrbier, A. Treatment of solid cancers. US8106092 (2012).
24. Suhrbier, A., Aylward, J., Parsons, P., Ogbourne, S. M., Lord, J., Scheel-Toellner, D. Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer. WO2007053912 (2007).
25. Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005; 106(4): 1362-8.
26. Chan PK, Zhao M, Che CT, Mak E. Cytotoxic acylated triterpene saponins from the husks of Xanthoceras sorbifolia. J Nat Prod 2008; 71(7): 1247-50.
27. Chan, P. K., Mak, M. S. New compounds for treating cancer and other diseases. WO2012009663 (2012).
28. Chan PK. Acylation with diangeloyl groups at C21-22 positions in triterpenoid saponins is essential for cytotoxicity towards tumor cells. Biochem Pharmacol 2007; 73(3): 341-50.
29. Chan, P. K., Mak, M. S., Wang, Y. Anti-tumor compounds with angeloyl groups. WO2006029221 (2006).
30. Chan, P. K., Mak, M. S. Anti-tumor compounds for inhibiting cancer growth. WO2008028060 (2008).
31. Chan, P. K., Mak, M. S. Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof. WO2008133766 (2008).
32. Roell D, Baniahmad A. The natural compounds atraric acid and Nbutylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol Cell Endocrinol 2011; 332: 1-8.
33. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10(2): 415-27.
34. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007; 96(8): 1159-65.
35. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57(10): 1829-34.
36. McGown AT, Fox BW. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 1989; 3(4): 249-54.
37. Meegan, M. J., Zisterer, D., Carr, M., Greene, T., O'Boyle, N., Greene, L. Combretastatin derivatives and uses therefor. WO2011073211 (2011).
38. Holwell SE, Cooper PA, Grosios K, Lippert JW, Pettit GR, Shnyder SD, et al. Combretastatin A-1 phosphate a novel tubulinbinding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res 2002; 22(2): 707-11.
39. Chaplin, D., Siim, B. G. Method for treating hematopoietic neoplasms. US20120270831 (2012).
40. Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW, et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004; 10(4): 1446-53.
41. Kerbel, R., Shaked, Y. Methods for enhancing the efficacy of vascular disrupting agents. US20110110940 (2011).
42. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102(9): 1355-60.
43. Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. A perspective on vascular disrupting agents that interact with tubulin: Preclinical tumor imaging and biological assessment. Integr Biol (Camb) 2011; 3(4): 375-87.
44. Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, et al. Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules. Curr Drug Metab 2011; 12: 944-55.
45. Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, et al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 2009; 15(13): 4484-92.
46. Cuevas C, Perez M, Martin MJ, Chicharro JL, Fernandez-Rivas C, Flores M, et al. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett 2000; 2(16): 2545-8.
47. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. Marine natural products as anticancer drugs. Mol Cancer Ther 2005; 4: 333-42.
48. Sakai R, Rinehart KL, Guan Y, Wang AH. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo. Proc Natl Acad Sci USA 1992; 89(23): 11456-60.
49. Scotto, K. A., Mandola, M. Use of PARP-1 inhibitors. US20090170860 (2009).
50. Rosell, R., Tarón, M., Martínez, N., Díez, A., Jimeno, J. M., Tercero, J. C. Prognostic molecular markers for ET-743 treatment. US20100267732 (2010).
51. Fontana A, Cavaliere P, Wahidulla S, Naik CG, Cimino G. A new antitumor isoquinoline alkaloid from the marine nudibranch Jorunna funebris. Tetrahedron 2000; 56(37): 7305-8.
52. Oku N, Matsunaga S, Van Soest RW, Fusetani N. Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp. J Nat Prod 2003; 66(8): 1136-9.
53. Guirouilh-Barbat J, Antony S, Pommier Y. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther 2009; 8(7): 2007-14.
54. De Bono, J., Paz-Ares, L., Tabernero, J., Smyth, J., De Las Heras, B. PM00104 compound for use in cancer therapy. WO2008135792 (2008).
55. Ocio, E., Pandiella, A., San Miguel, J., Avilés, P. M. Multiple myeloma treatments. US20110076343 (2011).
56. Carnero, A., Moneo, V. PDGFR-as response marker for PM00104 treatment. WO2011048210 (2011).
57. Coronado C, Galmarini CM, Alfaro V, Yovine A. Elisidepsin: Antineoplastic agent. Drugs Future 2010; 35(4): 287-96.
58. Hamann MT, Otto CS, Scheuer PJ, Dunbar DC. Kahalalides: Bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J Org Chem 1996; 61(19): 6594-600.
59. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2003; 2(9): 863-72.
60. Jackson, D. Y. Macrocyclic depsipeptide antibody-drug conjugates and methods. US20090226465 (2009).
61. Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, et al. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res 2008; 14(4): 1116-23.
62. Martin-Algarra S, Espinosa E, Rubio J, Lopez JJ, Manzano JL, Carrion LA, et al. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur J Cancer 2009; 45(5): 732-5.
63. Molina-Guijarro JM, Macias A, Garcia C, Munoz E, Garcia-Fernandez LF, David M, et al. Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS One 2011; 6(4): 19042.
64. Avilés, P. M., Cuevas, M. C. Depsipeptide for use in cancer therapy. WO2009135939 (2009).
65. Perez-Soler, R., Ling, Y. H., Jimeno, J. M., Zou, Y. Y. Improved antitumoral treatments. WO2009052379 (2009).
66. Xie XS, Padron D, Liao X, Wang J, Roth MG, De Brabander JK. Salicylihalamide A inhibits the V0 sector of the V-ATPase through a mechanism distinct from bafilomycin A1. J Biol Chem 2004; 279(19): 19755-63.
67. Baker, B., Diyabalanage, T., McClintock, J. B., Amsler, C. D. Cytotoxin compounds and methods of isolation. US20090192215 (2009).
68. Noguez JH, Diyabalanage TK, Miyata Y, Xie XS, Valeriote FA, Amsler CD, et al. Palmerolide macrolides from the Antarctic tunicate Synoicum adareanum. Bioorg Med Chem 2011; 19(22): 6608-14.
69. Ma B, Xiang Y, An L. Structural bases of physiological functions and roles of the vacuolar H(+)-ATPase. Cell Signal 2011; 23(8): 1244-56.
70. Forgac M. Vacuolar ATPases: Rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 2007; 8(11): 917-29.
71. Cichewicz RH, Valeriote FA, Crews P. Psymberin, a potent sponge-derived cytotoxin from Psammocinia distantly related to the pederin family. Org Lett 2004; 6(12): 1951-4.
72. Huang, X., Shao, N., Seidel-Dugan, C., Palani, A., Aslanian, R. G., Huryk, R. Novel psymberin derivatives, compositions, and their use as antineoplastic agents. WO2009158381 (2009).
73. Huang X, Shao N, Huryk R, Palani A, Aslanian R, Seidel-Dugan C. The discovery of potent antitumor agent C11-deoxypsymberin/irciniastatin A: Total synthesis and biology of advanced psymberin analogs. Org Lett 2009; 11(4): 867-70.
74. Wright AE, Botelho JC, Guzman E, Harmody D, Linley P, McCarthy PJ, et al. Neopeltolide, a macrolide from a lithistid sponge of the family Neopeltidae. J Nat Prod 2007; 70(3): 412-6.
75. Wright, A. E., Pomponi, S. A., McCarthy, P. J. Biologically active neopeltolide compounds. US7179828 (2007).
76. Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel 2009; 12(2): 189-96.
77. Reyes, J. F., Crespo, G., Fernández, R., Francesch, A., Cuevas, M. C. Antitumoral macrolides. US20110118343 (2011).
78. Aránega, A., Álvarez-Manzaneda, E., Chahboun, R., Rodríguez-Serrano, F., Boulaiz, H., Marchal, J. A., Melguizo, C., Perán, M., Prados, J. C. Synthetic analogues of merosesquiterpenes and related compounds having antitumoural activity. WO2010076358 (2010).
79. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31(1): 27-36.
80. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002; 108(4): 475-87.
81. Hoshino I, Matsubara H. Recent advances in histone deacetylase targeted cancer therapy. Surg Today 2010; 40(9): 809-15.
82. Willis-Martinez D, Richards HW, Timchenko NA, Medrano EE. Role of HDAC1 in senescence, aging, and cancer. Exp Gerontol 2010; 45(4): 279-85.
83. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today 2009; 14(19-20): 942-48.
84. Enokida H, Nakagawa M. Epigenetics in bladder cancer. Int J Clin Oncol 2008; 13(4): 298-307.
85. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994; 47(3): 301-10.
86. Verdine, G. L., Vrolijk, N. H. Romidepsin-based treatments for cancer. US20100093610 (2010).
87. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62(17): 4916-21.
88. Piekarz RL, Bates SE. Epigenetic modifiers: Basic understanding and clinical development. Clin Cancer Res 2009; 15(12): 3918-26.
89. Konstantinopoulos PA, Vandoros GP, Papavassiliou AG. FK228 (depsipeptide): A HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 2006; 58(5): 711-5.
90. Yang LP. Romidepsin: In the treatment of T-cell lymphoma. Drugs 2011; 71(11): 1469-80.
91. Vrolijk, N. Romidepsin solid forms and uses thereof. WO2012009336 (2012).
92. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 2011; 64(8): 525-31.
93. Keegan, M., Johnstone, R. W., Newbold, A., Cluse, L. Cancer therapy. WO2010047714 (2010).
94. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011; 13(5): 509-16.
95. Otterson GA, Hodgson L, Pang H, Vokes, EE. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 2010; 5(10): 1644-8.
96. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, et al. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther 2005; 313(1): 268-76.
97. Colabufo NA, Berardi F, Cantore M, Contino M, Inglese C, Niso M, et al. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: Pharmaceutical, biological, and diagnostic potentials. J Med Chem 2010; 53(5): 1883-97.
98. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55(11): 2325-33.
99. Park, B. S., Park, C. J., Lee, M. J., Hwang, Y. S. A novel myxobacteria strain and a method for preparing epothilone using the same. WO2011055991 (2011).
100. Ott PA, Hamilton A, Jones A, Haas N, Shore T, Liddell S, et al. A Phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One 2010; 5(1): 8714.
101. Heinz DW, Schubert WD, Hofle G. Much anticipated--the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed Engl 2005; 44(9): 1298-1301.
102. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008; 13(12): 1207-23.
103. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000; 1470(3): M79-91.
104. Huang, F., Carboni, J. Methods for treating cancer in patients having IGF-1R inhibitor resistance. US20120220594 (2012).
105. Harper, J., Lonning, S. M., Hsu, F. J. Combination therapy for treating breast cancer. WO2011112609 (2011).
106. DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, et al. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer 2010; 103(10): 1548-53.
107. Fenical, W. H., Jensen, P. R., Kwon, H. C. Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140. US7521414 (2009).
108. Fenical, W. H., Jensen, P. R., Mincer, T. J., Feling, R. H. Salinosporamides and methods for use thereof. US8217072 (2012).
109. Gulder TA, Moore BS. Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics. Angew Chem Int Ed Engl 2010; 49(49): 9346-67.
110. Goldberg AL. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007; 35(1): 12-17.
111. Bonavida, B., Palladino, M. Methods of sensitizing cancer to therapy-induced cytotoxicity. US20090148445 (2009).
112. Fenical W, Jensen PR, Palladino MA, Lam KS, Lloyd GK, Potts BC. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem 2009; 17(6): 2175-80.
113. Reddy LR, Saravanan P, Corey EJ. A simple stereocontrolled synthesis of salinosporamide A. J Am Chem Soc 2004; 126(20): 6230-1.
114. Yang, H. O., Kwon, H. C., Park, H. B., Yoo, J. H. The co-culture method of sphingomonas sp. bacterial strain and aspergillus sp. fungus strain, new anti-cancer and antibiotic glionitrins derived from this co-culture method, and pharmaceutical composition containing glionitrins or pharmaceutically acceptable salt thereof as an active ingredient. US20100215620 (2010).
115. Park HB, Kwon HC, Lee CH, Yang HO. Glionitrin A, an antibiotic-antitumor metabolite derived from competitive interaction between abandoned mine microbes. J Nat Prod 2009; 72(2): 248-52.
116. Park HB, Kim YJ, Park JS, Yang HO, Lee KR, Kwon HC. Glionitrin B, a cancer invasion inhibitory diketopiperazine produced by microbial coculture. J Nat Prod 2011; 74(10): 2309-12.
117. Méndez, C., Lombó, F., Fernández, A., Salas, J. A. Oviedomycin derivatives, method for obtaining same and use thereof. US20110207705 (2011).
118. Pettit, G. R., Tan, R. M., Pettit, R. K. Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth. US2010197570 (2010).
119. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents. J Nutr 2000; 130(2): 467-71.
120. Perecko T, Jancinova V, Drabikova K, Nosal R, Harmatha J. Structure-efficiency relationship in derivatives of stilbene. Comparison of resveratrol, pinosylvin and pterostilbene. Neuro Endocrinol Lett 2008; 29(5): 802-5.
121. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann NY Acad Sci 2011; 1215: 89-95.
122. Grant, R. S., Braidy, N., Guillemin, G., Smythe, G. Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders. WO2009108999 (2009).
123. Ye B, Aponte M, Dai Y, Li L, Ho MC, Vitonis A, et al. Ginkgo biloba and ovarian cancer prevention: Epidemiological and biological evidence. Cancer Lett 2007; 251(1): 43-52.
124. Ye, B., Cramer, D. Ginkgolides in the treatment and prevention of ovarian cancer. US20090099102 (2009).
125. Jeong JB, Jeong HJ, Park JH, Lee SH, Lee JR, Lee HK, et al. Cancer-preventive peptide lunasin from Solanum nigrum L. inhibits acetylation of core histones H3 and H4 and phosphorylation of retinoblastoma protein (Rb). J Agric Food Chem 2007; 55(26): 10707-13.
126. Jeong HJ, Jeong JB, Kim DS, de Lumen BO. Inhibition of core histone acetylation by the cancer preventive peptide lunasin. J Agric Food Chem 2007; 55(3): 632-7.
127. Hsieh CC, Hernandez-Ledesma B, de Lumen BO. Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact 2010; 186(2): 127-34.
128. Hernandez-Ledesma B, Hsieh CC, de Lumen BO. Relationship between lunasin's sequence and its inhibitory activity of histones H3 and H4 acetylation. Mol Nutr Food Res 2011; 55(7): 989-98.
129. Davis, K., Barnett, B., Cai, J., McConnell, E. Lunasin-containing complex and purification of lunasin from plants. WO2011060181 (2011).
130. Arif M, Pradhan SK, Thanuja GR, Vedamurthy BM, Agrawal S, Dasgupta D, et al. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J Med Chem 2009; 52(2): 267-77.
131. Mazzio, E. A., Soliman, K. F. Nutraceutical composition and method of use for treatment/prevention of cancer. US20100209388 (2010).
132. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004; 279(32): 33716-26.
133. Pterostilbene. Monograph. Altern Med Rev 2010; 15(2): 159-63.
134. Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke SO. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 2002; 50(12): 3453-7.
135. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011; 2011: 591356.
136. Patel B, Das S, Prakash R, Yasir M. Natural bioactive compound with anticancer potential. Int J Advan Pharmaceut Sci 2010; 1: 32-41.
137. Estrela, J. M., Asensio, G., Asensi, M. A., Obrador, E., Varea, M. T., Jordá, L., Ferrer, P., Segarra, R., Ortega, A., Benlloch, M. Combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. US8227510 (2012).
138. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 2007; 120(12): 2527-37.
139. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-98.
140. Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, et al. Nanotech revolution for the anti-cancer drug delivery through blood-brain-barrier. Curr Cancer Drug Targets 2012; 12: 186-96.
141. Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul 2006; 23: 582-92.
142. De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: A strategy to overcome blood-brain barrier. Curr Drug Metab 2012; 13: 61-9.
143. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005; 10(21): 1451-8.
144. Galdiero M, Caraglia M. Nanotechnological and biotechnological strategies for drug delivery. Curr Drug Metab 2012; 13: 2-3.
145. Caraglia M, Marra M, Misso G, Lamberti M, Salzano G, De Rosa G, et al. Tumour-specific uptake of anti-cancer drugs: The future is here. Curr Drug Metab 2012; 13: 4-21.
146. Liu, Z., Chiu, M., Chan, K., Havard, P., Chen, W. Curcumin compositions and uses thereof. WO2012024405 (2012).
147. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 2011; 4(8): 1158-71.
148. Lim ZZ, Li JE, Ng CT, Yung LY, Bay BH. Gold nanoparticles in cancer therapy. Acta Pharmacol Sin 2011; 32(8): 983-90.
149. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small 2008; 4(1): 26-49.
150. Kim CK, Ghosh P, Rotello VM. Multimodal drug delivery using gold nanoparticles. Nanoscale 2009; 1(1): 61-67.
151. DeLong RK, Reynolds CM, Malcolm Y, Schaeffer A, Severs T, Wanekaya A. Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules. Nanotechnol Sci Appl 2010; 3: 53-63.
152. Hosta, L., Pla, M., Cruz, L. J., Kogan, M., Albericio, F. Improved antitumoral treatments. WO2009095480 (2009).
153. Hosta L, Pla-Roca M, Arbiol J, Lopez-Iglesias C, Samitier J, Cruz LJ, et al. Conjugation of Kahalalide F with gold nanoparticles to enhance in vitro antitumoral activity. Bioconjug Chem 2009; 20(1): 138-46.
154. Dothager RS, Piwnica-Worms D. Nano in cancer: Linking chemistry, biology, and clinical applications in vivo. Cancer Res 2011; 71: 5611-5.